Abstract: The objective of this study was to evaluate the effect of apatinib on the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in SD rats and the inhibitory effects of apatinib on venlafaxine in rat and human liver microsomes. Twenty-one SD male rats were randomly divided into three groups (n = 7): group A (multiple dose of 40 mg/kg apatinib for 7 days), group B (single dose of 40 mg/kg apatinib) and group C (the control group). All samples were measured by UPLC-MS/ MS. The results indicated that a single dose of apatinib increased the AUC (0-t) , AUC (0-∞) and C max of both venlafaxine and O-desmethylvenlafaxine significantly, while Vz/F and CLz/F were decreased. As for group A, only AUC (0-t) and CLz/F of venlafaxine were changed, while no parameters of O-desmethylvenlafaxine were altered. In addition, apatinib was determined to be a mixed inhibitor of venlafaxine.
Venlafaxine (Ven), a serotonin-norepinephrine reuptake inhibitor (SNRI) with antidepressant and anxiolytic properties, is extensively used in psychiatric practice and provides a reasonable second-step choice for depressed patients [1] [2] [3] [4] . Studies have shown that Ven can enhance the excitability of contralateral anterior motor cortex, contralateral primary sensorimotor cortex, language cortices, and contralateral auxiliary motor area [5, 6] . Moreover, Ven can be used not only to treat vasomotor symptoms in women with breast cancer but also as an alternative to treat neuropathic pain [7] [8] [9] [10] . The major active metabolite of Ven is O-desmethylvenlafaxine (Odv), and the minor metabolite is N-desmethylvenlafaxine (Ndv); these two metabolites are metabolized to N, O-dimethyl venlafaxine (Ddv). [11] . Ven has multiple metabolites, and the metabolic process involves multiple cytochrome P450 enzymes, based on which, Ven is prone to drug-drug interactions. [12] Adverse drug reactions of Ven are dizziness, insomnia, decreased appetite, hypertension, sedation, anxiety, abdominal pain, headache and convulsions. [4, 13] Studies have found that when quetiapine is used in combination with Ven, there is a risk of restless leg syndrome, serotonin syndrome and neuroleptic malignant syndrome. [14] [15] [16] An 11-year retrospective study and a population-based cohort study investigated the toxicities and risk of several potential adverse outcomes of Ven in children and older people, respectively [17, 18] . Moreover, antidepressants were associated with relatively high morbidity and mortality indices. [19] .
Apatinib (Apa), which is also known as YN968D1, is the first oral VEGFR (vascular endothelial growth factor receptor) tyrosine kinase inhibitor [20] . As Apa was approved as a subsequent-line treatment for advanced gastric cancer (AGC) in China, it has been studied extensively and it has been reported that it can be used against other tumours, such as breast cancer, hepatocellular carcinoma, non-small-cell lung cancer (NSCLC), angiosarcoma and epithelial ovarian cancer (EOC) [21] [22] [23] [24] [25] [26] . Therefore, Apa will play an increasingly important role in the field of anticancer drugs. Moreover, Apa tended to inhibit the activities of some rat CYPs [27] .
It is common for patients with advanced cancer to have varying degrees of depression. A new meta-analysis based on structured clinical interviews indicated that one-third of cancer patients suffer from certain mental disorder during acute care [28] . Cancer patients with anxiety or depression not only have lower quality of life but are also at risk of increased mortality [29, 30] . In addition, emotional distress has been considered as the sixth vital sign in cancer care [31] . Furthermore, because of the close relationship between cancer and depression, oncologists are paying more and more attention to the need of identifying patients with depression and recommend them to seek psychiatric counselling. Under these circumstances, it is possible to combine anticancer drugs and antidepressants. In view of the potential of Apa in the field of anticancer drugs and the widespread use of Ven in the field of antidepressant drugs, it makes sense to study whether there is an interaction between the two drugs. To our knowledge, there are no studies regarding these two drugs in combination, but there are some similar methods about interactions of Ven and Apa with other compounds, like the effect of apigenin on Ven [32] and the effect of Apa on carvedilol [33] . In this study, we examined the pharmacokinetics of Ven in rats after administration of Apa Authors for correspondence: Hong-yu Zhou and Guo-xin Hu, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China (e-mails lxd54@163.com and hgx@wmu.edu.cn). * These authors contributed equally to this work. and identified the effect as well as the mechanisms of Apa on Ven in human and rat liver microsome.
Materials and Methods
Chemicals and reagents. Ven was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Odv was obtained from Fluorochem limited (Wesley, Derbyshire, UK). Dextromethorphan was provided by Sigma-Aldrich Company (St Louis, MO, USA), which was used as internal standard (IS). Apa was purchased from Beijing Sunflower and Technology Development Co., Ltd. Carboxymethylcellulose sodium salt (CMC-Na) was from Sigma-Aldrich Company (Shanghai, China). Methanol, formic acid and acetonitrile of liquid chromatography (LC) grade were purchased from Merck (Darmstadt, Germany). Pooled human and rat liver microsomes were purchased from Corning Life Sciences Co., Ltd. In vitro experiments. The 200-ll incubation system contained 1.6 ll Apa, 3.14 ll Ven, 175.26 ll 1 M potassium phosphate buffer (PBS), 10 ll rat liver microsomes (RLM) or human liver microsomes (HLM) and 10 ll NADPH (1 mM). Work solutions of Apa and Ven were both diluted by methanol. The experiment of inhibition percentage of Apa was measured by the generating rate of metabolite in the presence of 100 lM Apa (study group) compared with no inhibitor (control group). In the experiment of IC 50 determination, the concentration of Apa was set as 0.01, 0.1, 1, 10, 50 and 100 lM, while that of Ven was 100 lM, which is close to its K m value [32] . In the experiment of determining the inhibitory effect of Apa on Ven in RLM and HLM, the concentration of Apa was designed at 0, 2, 5 and 10 lM according to the IC 50 value, while the concentration of Ven was designed at 25, 50, 100, 200 lM according to the K m value. The entire incubation system was performed at 37°C, which was cooled to À80°C after incubation for 50 min. Then, 400 ll acetonitrile and 20 ll IS (5 lg/ml) were added to the mixture. After vortex mixing for 2 min. and centrifugation at 13,000 rpm for 10 min., the supernatant obtained was diluted by pure water (1:1) to be detected.
In vivo experiments. Twenty-one male Sprague-Dawley (SD) rats purchased from the Shanghai Animal Experimental Center were randomly divided into three groups (n = 7): multiple dose of 40 mg/kg Apa for 7 days (group A), single dose of 40 mg/kg Apa (group B) and the control group (group C). Before the in vivo experiments, the 21 rats were fasted for 12 hr and only provided water. When the experiment started, 40 mg/kg Apa was orally administered in group A and group B, while the same dose of CMC-Na was administered in group C. After 30 min., 20 mg/kg Ven was orally administered to all groups. Blood samples from the tail vein were collected at 0.083, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hr after Ven administration.
The plasma samples were obtained from the blood above which was centrifuged at 13,000 rpm for 10 min. 100 ll plasma was collected and then mixed with 20 ll IS (5 lg/ ml) and 200 ll acetonitrile in a 1.5-ml centrifuge tube. After 2-min vortexing and 10-min centrifugation, the supernatant was obtained and diluted by pure water (1:1). Then, the 2-ll mixture was injected for UPLC-MS/MS analysis.
Statistical analysis. The pharmacokinetic parameters were evaluated by DAS version 3.0, using the non-compartmental analysis. IC 50 and Lineweaver-Burk plot were calculated by GraphPad Prism 5.0. The mean concentration-time curve was drawn by Origin 8.0. Statistical analysis of all data was expressed as mean AE S.D. and analysed via SPSS 19.0. p < 0.05 represented statistical significance.
Results

UPLC-MS/MS.
The calculated correlation coefficients of the quantitative calibration curve of Ven and Odv were both greater than 0.99. The concentration used ranged from 0.2 to 100 lg/ml for Ven and 0.4 to 100 lg/ml for Odv. The chromatograms of Ven, Odv and IS are shown in fig. 1 . 
Effects of Apa on the metabolism of Ven in vitro.
The inhibitory effects of Apa (100 lM) on the Ven in HLM and RLM were obvious; inhibition percentages were 94.95% and 90.95%, respectively. Fig. 2 fig. 3 . The Ki and aKi values in RLM and HLM were extremely close (table 1) . The results indicated that Apa inhibited Ven by a mixed way.
Effects of Apa on the metabolism of Ven in vivo.
The mean concentration-time curves of Ven and Odv in three groups are shown in fig. 4 , and the corresponding parameters of pharmacokinetics are shown in tables 2 and 3. When comparing group A to group C (control group), the value of AUC (0-t) of Ven increased while CLz/F of Ven decreased, but no parameters of Odv significantly changed. When comparing group B to group C, the values of Vz/F and CLz/F of both Ven and Odv were decreased, while the values of AUC (0-t) , AUC (0-∞) and C max of both Ven and Odv were significantly increased.
Discussion
The results of the in vivo experiment revealed that Apa has an influence on the metabolism of Ven, which may cause drugdrug interactions (DDIs). A single dose of Apa increased the AUC (0-t) , AUC (0-∞) and Cmax of Ven significantly, while Vz/F and CLz/F were decreased, indicating inhibition of Apa on Ven. The in vitro study also indicated that the inhibitory effect of Apa on Ven in RLM and HLM was both strong with IC 50 <10 lM [34] , making a good accordance with the in vivo pharmacokinetics study. Interestingly, the influence of multiple dose of Apa on Ven was not that obvious, with only CLz/F decreased and Cmax increased. The reason why long-term administration and short-term administration influenced the metabolism of Ven in a different degree might be the presence of enzyme induction. As the number of Apa administrations increased, the inhibitory effect of Apa on Ven attenuated. To further study the inhibition of Ven by Apa, we investigated the inhibition mechanism in RLM and HLM. The results indicated that Apa inhibited Ven by a mixed way in both RLM and HLM. Further, the Ki and aKi values were almost the same both in RLM and in HLM, demonstrating that the effect of Apa on the metabolism of Ven in rats can be analogized to human beings to a certain degree.
The metabolism of Ven is complex, and it is first metabolized into its main active metabolite Odv and the secondary metabolite N-desmethylvenlafaxine (Ndv). Then, these two metabolites are metabolized to N,O-didesmethylvenlafaxine (Ddv) [11] . The metabolic process of Ven involved CYP2D6, CYP3A4, CYP2C19 and CYP2C9 [35] . Apa was metabolized by CYP3A4/5, CYP2D6, CYP2C9 and CYP2E1 [36] . Coincidentally, these two drugs shared three CYP metabolic pathways, which may be the reason of the in vitro results of Apa inhibiting Ven by a mixed way and the in vivo results of Apa influencing the metabolism of Ven and Odv. Moreover, Apa was reported to be a potential inhibitor of rat CYP2D4 and CYP3A1 [27] , which might lead to the inhibition of Ven and Odv metabolism to Ddv. Although our work was mostly based on rats, studies have pointed out that human CYP1A2, CYP2C9 and CYP2D share a high sequence identity (>70%) with rat CYP 1A2, CYP2C11 and CYP2D, respectively. [37] Therefore, our study also has a certain significance for clinical application. Clinically, the total concentration of Ven and Odv is used as therapeutic concentration [38] . Therefore, the effect of Apa on the metabolism of Odv is particularly important. Our results of the in vivo experiment showed that the effect of a single dose of apatinib on the pharmacokinetics of Odv was basically the same as that of Ven, whereas in the long-term group, Apa had no significant effect on Odv.
In conclusion, the results showed that Apa inhibited the metabolism of Ven in vitro by a mixed way, and the effect of Apa in a single-dose group on the metabolism of Ven and Odv in rat was more significant than that of the long-term administration group. Given that there is a great possibility of combining Apa and Ven, our study should be considered significant in guiding clinical treatment.
